Latest news with #Hoffmann-LaRoche
Qatar Tribune
19-06-2025
- Health
- Qatar Tribune
MoPH strengthens health technology assessment in Qatar
DOHA: The Ministry of Public Health (MoPH) has highlighted its commitment to strengthening national capabilities in Health Technology Assessment (HTA) and health policy, having established a dedicated national unit in this field and developed a comprehensive assessment framework with clear standards. These efforts come as part of the twelfth outcome, "Excellence in Health Research, Development, and Innovation," under the third priority, "Efficiency and Resilience of the Health System," in the National Health Strategy 2024–2030. In that context, the MoPH has recently organized a high-level workshop to enhance national capacities in HTA and health policy, in collaboration with the London School of Economics and Political Science (LSE) and Hoffmann-La Roche. The workshop formed part of the Ministry's ongoing efforts to entrench evidence-based decision-making across healthcare sectors and to promote long-term sustainability and resilience within Qatar's health system. The workshop reflected the MoPH's commitment to ensuring the effective and equitable allocation of health resources, supporting innovation through effective governance of emerging technologies, and enhancing the overall resilience and sustainability of the health system. It also underscored the importance of multi-sectoral partnerships in achieving national health priorities. These efforts align with the goals of the Human Development Pillar of Qatar National Vision 2030 and the priorities of the National Health Strategy, particularly in building a high-performing, efficient, person-centered, data-driven health system that is responsive to current and future health needs. The workshop was opened by Head of the National Health Technology Assessment Unit Project within the National Health Strategy at the MoPH Dr Anas Hamad emphasized the importance of concerted efforts to achieve the Ministry's objectives under its 2024–2030 strategy, improve health system outcomes, and build specialized national capacities in this field. Dr Hamad said: "The project to establish a national HTA unit is based on the third priority of the National Health Strategy, which focuses on efficiency and resilience, and is part of the twelfth outcome relating to excellence in research, development, and innovation. The HTA project is a pivotal initiative to develop an integrated and reliable framework to support transparent, evidence-based decision-making within Qatar's health system. Through systematic evaluation of the clinical, economic, and social impacts of modern health technologies, we aim to ensure the best health value for citizens and residents, and to enhance the sustainability of Qatar's health system. This workshop is a foundational step for this project, which will contribute to achieving a sustainable, high-quality, efficient, patient-centered, and prudent health system that meets the needs of current and future generations." In turn, General Manager of Hoffmann-La Roche in the Gulf region Dr Ahmed Tawfiq stressed the importance of unifying efforts between the public and private sectors to develop sustainability frameworks aligned with shared objectives. Dr Tawfiq said: "Today, we are working with our partners at the Ministry of Public Health and the London School of Economics and Political Science to achieve a shared goal of improving healthcare in Qatar, in line with Qatar National Vision 2030. By building capacity in health technology assessment, we ensure that the right treatments reach the right patients at the right time, relying on the latest scientific evidence and modern technologies." Chair in Health Policy and Director of the LSE Health Centre at the London School of Economics and Political Science Professor Elias Mossialos said: "The LSE is proud to deliver an intensive two-day training program for the Ministry of Public Health in Qatar, focusing on key trends in healthcare, disease prevention and early diagnosis, and economic evaluation in healthcare as an essential tool for improving system performance and decision-making, in addition to HTA programs and value-based frameworks introduced by health innovations." The workshop provided participants with a comprehensive and in-depth understanding of the frameworks, capabilities, and key factors required to build an effective HTA structure. The focus was on applying real-world evidence to inform policy and investment decisions, and laying the foundation for the systematic and organized use of economic evaluation within Qatar's health policy framework.
Qatar Tribune
18-06-2025
- Health
- Qatar Tribune
MoPH boosts health tech assessment in Qatar
Tribune News Network Doha The Ministry of Public Health (MoPH) recently organised a high-level workshop to enhance national capacities in Health Technology Assessment (HTA) and health policy in collaboration with the London School of Economics and Political Science (LSE) and Hoffmann-La Roche. The workshop formed part of the ministry's ongoing efforts to entrench evidence-based decision-making across healthcare sectors and to promote long-term sustainability and resilience within Qatar's health system. The workshop aimed to strengthen national capabilities in HTA and health policy. Establishing a dedicated national unit in this field and developing a comprehensive assessment framework with clear standards are part of the twelfth outcome, 'Excellence in Health Research, Development, and Innovation,' under the third priority, 'Efficiency and Resilience of the Health System,' in the National Health Strategy 2024–2030. The workshop reflected the ministry's commitment to ensuring the effective and equitable allocation of health resources, supporting innovation through effective governance of emerging technologies, and enhancing the overall resilience and sustainability of the health system. It also underscored the importance of multi-sectoral partnerships in achieving national health priorities. These efforts align with the goals of the Human Development Pillar of Qatar National Vision 2030 and the priorities of the National Health Strategy, particularly in building a high-performing, efficient, person-centred, data-driven health system that is responsive to current and future health needs. The workshop was opened by Dr Anas Hamad, head of the National Health Technology Assessment Unit Project within the National Health Strategy at the Ministry of Public Health, who emphasised the importance of concerted efforts to achieve the ministry's objectives under its 2024–2030 strategy, improve health system outcomes, and build specialised national capacities in this field. He said, 'The project to establish a national Health Technology Assessment (HTA) unit is based on the third priority of the National Health Strategy, which focuses on efficiency and resilience, and is part of the twelfth outcome relating to excellence in research, development, and innovation. The HTA project is a pivotal initiative to develop an integrated and reliable framework to support transparent, evidence-based decision-making within Qatar's health system. 'Through systematic evaluation of the clinical, economic, and social impacts of modern health technologies, we aim to ensure the best health value for citizens and residents, and to enhance the sustainability of Qatar's health system. This workshop is a foundational step for this project, which will contribute to achieving a sustainable, high-quality, efficient, patient-centred, and prudent health system that meets the needs of current and future generations.' Dr Ahmed Tawfiq, general manager of Hoffmann-La Roche in the Gulf region, stressed the importance of unifying efforts between the public and private sectors to develop sustainability frameworks aligned with shared objectives. He said, 'Today, we are working with our partners at the Ministry of Public Health and the London School of Economics and Political Science to achieve a shared goal of improving healthcare in Qatar, in line with Qatar National Vision 2030. By building capacity in health technology assessment, we ensure that the right treatments reach the right patients at the right time, relying on the latest scientific evidence and modern technologies.' Professor Elias Mossialos, chair in Health Policy and director of the LSE Health Centre at the London School of Economics and Political Science, said: 'The LSE is proud to deliver an intensive two-day training programme for the Ministry of Public Health in Qatar, focusing on key trends in healthcare, disease prevention and early diagnosis, and economic evaluation in healthcare as an essential tool for improving system performance and decision-making, in addition to HTA programmes and value-based frameworks introduced by health innovations.' Through lectures and discussions over two days, delivered and moderated by Professor Elias Mossialos, Dr Panos Kanavos, and Dr Alex Carter, the workshop provided participants with a comprehensive and in-depth understanding of the frameworks, capabilities, and key factors required to build an effective HTA structure. The focus was on applying real-world evidence to inform policy and investment decisions, and laying the foundation for the systematic and organised use of economic evaluation within Qatar's health policy framework.
Globe and Mail
26-03-2025
- Business
- Globe and Mail
Non-Hodgkin's Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Non-Hodgkin Lymphoma Pipeline Insight 2025' report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in the Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin's Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin's Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Non-Hodgkin's Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Non-Hodgkin's Lymphoma Pipeline Outlook Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report In March 2025, Hoffmann-La Roche conducted a phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma. In March 2025, Bristol-Myers Squibb organized a phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma. DelveInsight's Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working to develop 220+ pipeline therapies for Non-Hodgkin Lymphoma treatment. The leading Non-Hodgkin Lymphoma Companies such as Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others. Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others. Stay ahead with the most recent pipeline outlook for Non-Hodgkin's Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-Hodgkin's Lymphoma Treatment Drugs Non-Hodgkin Lymphoma Emerging Drugs Profile Mosunetuzumab: Hoffmann-la Roche Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3e), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies. This results in crosslinking of the TCR, inducing downstream signaling events that lead to B-cell killing. Mosunetuzumab is equipped with structural features that promote T-cell recruitment and retention, resulting in an antitumor effect. In preclinical models, mosunetuzumab induced T-cell proliferation and B-cell death; furthermore, efficient B-cell killing was achieved at low effector-to-target (T cell:B cell) ratios. Use of mosunetuzumab in combination with PD-L1 inhibition may address adaptive immune resistance mechanisms to enhance anticancer activity against B-cell malignancies. The drug is being evaluated in Phase III Study to evaluate the efficacy and safety of Mosunetuzumab in combination with Polatuzumab Vedotin in comparison with rituximab in combination with gemcitabine plus oxaliplatin in participants with relapsed or refractory aggressive b-cell Non-Hodgkin's Lymphoma. Tisagenlecleucel: Novartis Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy that involves genetically modified autologous T cells isolated from each individual patient. The reprogramming of the patient's T cells uses a lentiviral vector to encode an anti-CD19 chimeric antigen receptor (CAR). The CAR is comprised of a murine single-chain antibody fragment (scFv) specific for CD19, followed by a CD8 hinge and transmembrane region that is fused to the intracellular signaling domains from 4-1BB (CD137) and CD3 zeta Label. These intracellular costimulatory signaling domains increase the expansion, longer-term persistence and potency of CAR T cells: the CD3 zeta component is critical for initiating T-cell activation and antitumor activity, while 4-1BB enhances the expansion and persistence of tisagenlecleucel {FDA Label, A20379]. Upon binding to CD19-expressing cells, the CAR transmits a signal to promote T-cell expansion, activation, target cell elimination, and persistence of the tisagenlecleucel cells. Currently, it is in Phase III stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma. Capivasertib: AstraZeneca Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma. BI-1206: BioInvent BI-1206 is a high-affinity monoclonal antibody that selectivity binds to Fc?RIIB (CD32B), the only inhibitory member of the Fc?R family. Fc?RIIB is overexpressed in several forms of NHL and overexpression has been associated with poor prognosis in difficult-to treat forms of NHL, such as mantle cell lymphoma. By blocking Fc?RIIB, BI-1206 is expected to recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of these diseases. In January 2023, positive data was presented from the ongoing clinical Phase I/IIa study of BI-1206 in combination with rituximab for the treatment of non-Hodgkin's lymphoma (NHL). Data suggest that BI-1206 restores activity of rituximab in relapsed NHL patients. HMPL-760: Hutchmed HMPL-760 is an investigational, highly selective, non-covalent, third-generation inhibitor of BTK, both wild-type and C481S mutant enzymes, with pre-clinical data suggesting high target specificity and higher potency versus first generation BTK inhibitors. BTK C481S mutation plays an important role in resistance to certain BTK inhibitors. The Non-Hodgkin's Lymphoma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin's Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin's Lymphoma Treatment. Non-Hodgkin's Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Non-Hodgkin's Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin's Lymphoma market Explore groundbreaking therapies and clinical trials in the Non-Hodgkin's Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Non-Hodgkin's Lymphoma Drugs Non-Hodgkin's Lymphoma Companies Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences Inc. and others. Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral intravenous Subcutaneous Topical Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Unveil the future of Non-Hodgkin's Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Non-Hodgkin's Lymphoma Market Drivers and Barriers Scope of the Non-Hodgkin Lymphoma Pipeline Report Coverage- Global Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Non-Hodgkin Lymphoma Companies- Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others. Non-Hodgkin Lymphoma Pipeline Therapies- Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others. Get the latest on Non-Hodgkin's Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Non-Hodgkin's Lymphoma Companies, Key Products and Unmet Needs Table of Content Introduction Non-Hodgkin's Lymphoma Executive Summary Non-Hodgkin Lymphoma: Overview Non-Hodgkin's Lymphoma Pipeline Therapeutics Non-Hodgkin's Lymphoma Therapeutic Assessment Non-Hodgkin Lymphoma – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Tisagenlecleucel: Novartis Drug profiles in the detailed report….. Mid Stage Products (Phase II) Capivasertib: AstraZeneca Drug profiles in the detailed report….. Early Stage Products (Phase I/II) BI-1206: BioInvent Drug profiles in the detailed report….. Early Stage Products (Phase I) HMPL-760: Hutchmed Drug profiles in the detailed report….. Preclinical Stage Products Product Name: Company Name Drug profiles in the detailed report….. Inactive Products Non-Hodgkin Lymphoma Key Companies Non-Hodgkin Lymphoma Key Products Non-Hodgkin Lymphoma- Unmet Needs Non-Hodgkin Lymphoma- Market Drivers and Barriers Non-Hodgkin Lymphoma- Future Perspectives and Conclusion Non-Hodgkin Lymphoma Analyst Views Non-Hodgkin Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
25-02-2025
- Business
- Globe and Mail
ALK-positive Non-Small Cell Lung Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Insight' report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the ALK-positive Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ALK-positive Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the ALK-positive Non-Small Cell Lung Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ ALK-positive Non-Small Cell Lung Cancer Pipeline Outlook Key Takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report In February 2025:- Novartis Pharmaceuticals:- The primary purpose of the study was to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib. Patients in the chemotherapy arm were given the option to switch to LDK378 after confirmed progressive disease (PD), while also had the choice to continue with pemetrexed treatment. In February 2025:- Hoffmann-La Roche:- A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer. In February 2025:- Takeda:- All participants will be asked to take brigatinib or alectinib at the same time each day throughout the study. For each participant eligible to continue in the study and to facilitate the remaining participants from Brigatinib-2002 (NCT03535740) to have continued treatment access, the study extension phase may be initiated for participants to continue receiving their randomized study treatment (i.e., brigatinib or alectinib) until they meet at least one of the treatment discontinuation criteria. DelveInsight's ALK-positive Non-Small Cell Lung Cancer pipeline report depicts a robust space with 6+ active players working to develop 7+ pipeline therapies for ALK-positive Non-Small Cell Lung Cancer treatment. The leading ALK-positive Non-Small Cell Lung Cancer Companies such as Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others. Promising ALK-positive Non-Small Cell Lung Cancer Therapies such as Lorlatinib, XZP-3621, X-396 (ensartinib), Crizotinib, WX-0593, SAF-189s, and others. Stay ahead with the most recent pipeline outlook for ALK-positive Non-Small Cell Lung Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ ALK-positive Non-Small Cell Lung Cancer Treatment Drugs ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile SY-3505: Shouyao Holdings Ficonalkib (SY-3505) is a highly potent, adenosine triphosphate-competitive, CNS-penetrant, 3rd-gen ALK TKI. In vitro kinase assay revealed that ficonalkib exhibits potent inhibition against both wild-type ALK and a diverse spectrum of mutants observed in patients resistant to 1st- and 2nd-gen ALK TKI, including L1196M, G1202R, F1174L, G1269S, and R1275Q20. The drug exhibits high kinase selectivity and has very weak inhibition on tropomyosin receptor kinase (TRK). The drug is currently being evaluated under Phase III clinical trials for the treatment of NSCLC. APG-2449: Ascentage Pharma APG-2449 is an orally available, small-molecule FAK/ALK/ROS1 TKI and the first China-developed third-generation ALK inhibitor entering clinical development. The updated results at the ASCO indicated favorable safety and promising antitumor activity in patients with NSCLC, and the preliminary efficacy observed in patients who were resistant to second-generation ALK inhibitors was particularly encouraging. APG-2449 is currently being evaluated in Phase I clinical trial for Non-Small Cell Lung Cancer. Explore groundbreaking therapies and clinical trials in the ALK-positive Non-Small Cell Lung Cancer Pipeline. Access DelveInsight's detailed report now! @ New ALK-positive Non-Small Cell Lung Cancer Drugs ALK-positive Non-Small Cell Lung Cancer Companies Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others ALK-positive Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Oral Parenteral Subcutaneous Topical Transdermal ALK-positive Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Unveil the future of ALK-positive Non-Small Cell Lung Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ ALK-positive Non-Small Cell Lung Cancer Market Drivers and Barriers Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report Coverage- Global ALK-positive Non-Small Cell Lung Cancer Companies- Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others. ALK-positive Non-Small Cell Lung Cancer Therapies- Lorlatinib, XZP-3621, X-396 (ensartinib), Crizotinib, WX-0593, SAF-189s, and others. ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on ALK-positive Non-Small Cell Lung Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ ALK-positive Non-Small Cell Lung Cancer Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary ALK Positive Non-Small Cell Lung Cancer : Overview Pipeline Therapeutics Therapeutic Assessment ALK Positive Non-Small Cell Lung Cancer – DelveInsight's Analytical Perspective Late Stage Products (Phase III) SY-3505: Shouyao Holdings Drug profiles in the detailed report….. Mid Stage Products (Phase II) Product Name: Company Name Drug profiles in the detailed report….. Early Stage Products (Phase I) APG-2449: Ascentage Pharma Drug profiles in the detailed report….. Preclinical Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products ALK Positive Non-Small Cell Lung Cancer - Collaborations Assessment- Licensing / Partnering / Funding ALK Positive Non-Small Cell Lung Cancer - Unmet Needs ALK Positive Non-Small Cell Lung Cancer - Market Drivers and Barriers Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
18-02-2025
- Business
- Globe and Mail
Liver Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Liver Cancer Pipeline Insight' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Liver Cancer pipeline landscape. It covers the Liver Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Liver Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Liver Cancer Pipeline Report to explore emerging therapies, key Liver Cancer Companies, and future Liver Cancer treatment landscapes @ Liver Cancer Pipeline Outlook Report Key Takeaways from the Liver Cancer Pipeline Report In February 2025:- Imperial College London:- Open label, single arm, multi-centre studyof pembrolizumab following trans-arterial chemoembolization (TACE). Twenty-six to 32 evaluable participants with primary liver cancer (hepatocellular cancer; HCC) will be assessed. The primary objective is to determine the safety and tolerability of pembrolizumab following TACE. The secondary objective is to evaluate the efficacy of pembrolizumab following TACE by improving progression-free survival rates as measured by modified response evaluation criteria in solid tumours (mRECIST) criteria. In February 2025:- Hoffmann-La Roche:- This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. In February 2025:- Eisai Inc.:- The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only). DelveInsight's Liver Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Liver Cancer treatment. The leading Liver Cancer Companies such as Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, Bristol-Myers Squibb and others. Promising Liver Cancer Therapies such as Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others. Discover how the Liver Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Liver Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Liver Cancer Clinical Trials and Studies Liver Cancer Emerging Drugs Profile Namodenoson: Can-Fite BioPharma Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5'- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson's mechanism of action is mediated via deregulation of the NF-κB and Wnt signal transduction pathways, resulting in the apoptosis of tumor cells. The protective effect of Namodenoson is mediated via down-regulation of the NF-kB signal transduction pathway and preventing apoptosis. Namodenoson has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation. The safety of Namodenoson has been demonstrated in preclinical studies, and Phase I and Phase II clinical studies demonstrating a favorable safety profile. Currently, the drug is in Phase III stage of its development for the treatment of advanced liver Cancer. YIV-906: Yiviva YIV-906 (also PHY906 or KD018) is a therapeutic candidate comprised of a proprietary cGMP botanical extract of four herbs inspired by a traditional Chinese medicine formulation used for over a millennium. YIV-906 has the potential to be developed as a platform oncology therapeutic when administered in combination with chemotherapy, immunotherapy and radiation therapies, in multiple cancer indications. YIV-906 has been shown to enhance immune function in the tumor microenvironment (by polarizing M1 macrophages and activating T cells), protect the gastrointestinal tract (by inhibiting inflammation via IL-6, NF-kappa-B, COX2, and iNOS pathways) and promote intestinal tissue repair (by increasing activity and expression of components of the Wnt signaling pathway). YIV-906 has been observed to enhance the anti-tumor activity of sorafenib in preclinical models of hepatocellular carcinoma and has shown promise in preliminary clinical studies in liver, pancreatic, colorectal and rectal cancers. Currently, the drug is in phase II stage of its clincal trial for the treatment of liver cancer. TTI-101: Tvardi Therapeutics TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in attenuating pY705-STAT3 phosphorylation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. Currently, the drug is in phase II stage of clinical trial. STP707, our second key product, is in early-stage development for the treatment of solid tumors, liver cancer. STP707 is an intravenously administered TGF-ß1 and COX-2 inhibitor that leverages an RNAi-based response using the company's proprietary PNP delivery platform. Currently, the drug is in Phase I stage of its clinical trial for the treatment of liver cancer. BST02: BioSyngen BST02, a T cell therapy based on the expansion of the patient's own tumor infiltrating lymphocytes, falls within the category of adoptive immune cell therapy technology. It holds promise for the treatment of all types of liver cancer, offering new hope for patients. In contrast to traditional TIL therapies, BST02 offers numerous benefits, including the ability to overcome distance constraints due to its cryopreserved form and the reduced need for high doses of interleukin-2. Currently, the drug is in Phase I stage of its clinical trial for the treatment of liver cancer. The Liver Cancer pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Liver Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Cancer Treatment. Liver Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Liver Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liver Cancer market. Liver Cancer Companies Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, Bristol-Myers Squibb and others. Liver Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Oral Parenteral Subcutaneous Topical Transdermal Liver Cancer Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Download DelveInsight's latest report to gain strategic insights into upcoming Liver Cancer Therapies and key Liver Cancer Developments @ Liver Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Liver Cancer Pipeline Report Coverage- Global Liver Cancer Companies- Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, and Bristol-Myers Squibb, and others. Liver Cancer Therapies- Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others. Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Liver Cancer drug development? Find out in DelveInsight's exclusive Liver Cancer Pipeline Report—access it now! @ Liver Cancer Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Liver Cancer: Overview Pipeline Therapeutics Therapeutic Assessment Liver Cancer – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Namodenoson: Can-Fite BioPharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) YIV-906: Yiviva Drug profiles in the detailed report….. Early Stage Products (Phase I) STP707: Sirnaomics Mid Stage Products (Phase II) Preclinical Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Liver Cancer - Collaborations Assessment- Licensing / Partnering / Funding Liver Cancer - Unmet Needs Liver Cancer - Market Drivers and Barriers Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
